- Shopping Bag ( 0 items )
From The CriticsReviewer: Gregory Reed, PhD (University of Kansas Medical Center)
Description: The editors set out to assemble a textbook covering all stages of drug development for the specific area of anticancer agents, from the identification of promising molecular targets through the submission of an NDA.
Purpose: It is intended to serve as a single-source text and reference for clinical pharmacologists, pharmaceutical scientists, and physicians interested in anticancer drug development. To have all relevant topics covered in a single book would provide an exceptional reference. This book achieves about 90 percent of this goal.
Audience: The book is written for advanced readers, such as a senior graduate students, residents, or post-doctoral fellows. It should readily serve the needs of those new to drug development and clinical pharmacology, as well as provide a reference and refresher course for those with more experience.
Features: Chapters cover the selection of molecular targets for anticancer therapies, preclinical screening in vitro and in vivo for pharmacologic properties and efficacy, the development and validation of analytical methods, aspects of pharmacokinetics and pharmacodynamics, and selected aspects of designing clinical trials. Several chapters address special populations and unique routes of administration. Pharmacologic aspects of biological agents (vaccines, antibodies, cytokines) are covered. Some issues are missing, such as preclinical toxicology, and some, such as molecular targets, could benefit from more in-depth presentation.
Assessment: Overall, however, the book and the references should be of great value to those entering the field or those already involved in anticancer drug development.